Microarray data from patients samples with triple negative breast cancer

The genomic studies was designed to identify genes differentially expressed in tumor versus normal breast tissue. We aimed at identifying novel Antibody Drug Conjugate (ADC) targets that could be used to treat Triple Negative Breast Cancer (TNBC). Comparative genomic studies between normal breast and TNBC tissues, together with proteomic and bioinformatic analyses resulted in the elaboration of a catalog of potential ADC targets. Samples were obtained at the University Hospital (Department of Pathology) of Salamanca from patients with triple negative breast cancer. One sample from normal breast tissue was also obtained.